Cargando…

Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Lu, Yi, Gao, Yue, Yang, Huan, Hu, Yong, Li, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878760/ https://www.ncbi.nlm.nih.gov/pubmed/36698203 http://dx.doi.org/10.1186/s40779-023-00440-4

Ejemplares similares

Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
por: Lu, Yi, et al.
Publicado: (2022)

Correction: Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2018)

Investigating the effect of Icaritin on hepatocellular carcinoma based on network pharmacology
por: Xue, Zhong, et al.
Publicado: (2023)

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
por: Gao, Jing, et al.
Publicado: (2020)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
por: Qin, Shu‐Kui, et al.
Publicado: (2020)

Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells
por: Lu, Pei-Hua, et al.
Publicado: (2017)

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
por: Fan, Ying, et al.
Publicado: (2019)

Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects
por: Gao, Lifang, et al.
Publicado: (2022)

Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma
por: Li, Hui, et al.
Publicado: (2021)

Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma
por: Li, Shasha, et al.
Publicado: (2013)

A comparative study on the in vitro and in vivo antitumor efficacy of icaritin and hydrous icaritin nanorods
por: Li, Haowen, et al.
Publicado: (2020)

Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
por: Chen, Qinjun, et al.
Publicado: (2021)

Application of Nanomedicine in Immunotherapy: Recent Advances and Prospects
por: Longo, João Paulo Figueiró, et al.
Publicado: (2023)

Pharmacokinetics and metabolism of icaritin in rats by UPLC‐MS/MS
por: Huang, Zhen‐Wu, et al.
Publicado: (2019)

Correction: Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Publicado: (2023)

Correction to: Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective
por: López-Méndez, Tania B., et al.
Publicado: (2023)

Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis
por: Li, Yue, et al.
Publicado: (2018)

Correction to: Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma
por: Lu, Chenying, et al.
Publicado: (2020)

Nanomedicine and cancer immunotherapy
por: Yu, Hai-jun, et al.
Publicado: (2020)

Correction: LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma
por: Hu, Jiangfeng, et al.
Publicado: (2018)

Peripubertal Administration of Icariin and Icaritin Advances Pubertal Development in Female Rats
por: Kang, Hyun Ku, et al.
Publicado: (2012)

Induction of ROS and DNA damage-dependent senescence by icaritin contributes to its antitumor activity in hepatocellular carcinoma cells
por: Wang, Shikang, et al.
Publicado: (2019)

Correction to: Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics
por: Choi, Young Hee, et al.
Publicado: (2018)

Advances in immunotherapy for hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2021)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Publisher Correction: ‘TRAIL-based gene delivery and therapeutic strategies’ and ‘Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy’
por: Zhong, Hui-ha, et al.
Publicado: (2020)

Engineering Prodrug Nanomedicine for Cancer Immunotherapy
por: Yang, Bin, et al.
Publicado: (2020)

Correction to: Differentiation between combined hepatocellular cholangiocarcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017
por: Li, Chao-qun, et al.
Publicado: (2022)

Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation
por: Tao, Huimin, et al.
Publicado: (2021)

Correction to: MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming
por: Liu, Yang, et al.
Publicado: (2020)

Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
por: Segura-Collar, Berta, et al.
Publicado: (2023)

Activation of cancer immunotherapy by nanomedicine
por: Wang, Lijuan, et al.
Publicado: (2022)

Nanomedicine in Lung Cancer Immunotherapy
por: Doroudian, Mohammad, et al.
Publicado: (2023)

Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma
por: Zhu, Qing, et al.
Publicado: (2021)

Icaritin inhibits decidualization of endometrial stromal cells
por: Le, Aiwen, et al.
Publicado: (2017)

Icaritin, an Exogenous Phytomolecule, Enhances Osteogenesis but Not Angiogenesis—An In Vitro Efficacy Study
por: Yao, Dong, et al.
Publicado: (2012)

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
por: Nakano, Shigeharu, et al.
Publicado: (2020)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hgf2anshqoi9ksd51bh939sens